| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 01/24/2001 | CN1060944C Compound bismuth aluminate granule and preparing process |
| 01/24/2001 | CN1060938C Chinese medicinal instant powder for treatment of B-hepatitis |
| 01/23/2001 | US6177550 Process for extraction of a growth factor complex |
| 01/23/2001 | US6177451 For humans; parkinson's, tourelle's, and alzheimer's diseases |
| 01/23/2001 | US6177444 Allosteric adenosine receptor modulators |
| 01/23/2001 | US6177429 Dihydropyrazine derivatives as NPY antagonists |
| 01/23/2001 | US6177428 Treatment of sexual dysfunction; stimulation of endogenous nitrogen monoxide synthesis |
| 01/23/2001 | US6177426 Morpholino-N-ethyl ester prodrugs of indole sPLA2 inhibitors |
| 01/23/2001 | US6177419 Antioxidant chelate compounds for preventing oxygen free radical-associated diseases in mammals; neuroprotectants, superoxide dismutase (sod), catalase (cat) and/or peroxidase (pod) mimetics |
| 01/23/2001 | US6177401 Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| 01/23/2001 | US6177096 Water soluble film for oral administration with instant wettability |
| 01/23/2001 | CA2314473A1 New b-carboline derivatives, a procedure for preparing them and the pharmaceutical compounds containing them |
| 01/18/2001 | WO2001004318A2 Myxoma virus genes for immune modulation |
| 01/18/2001 | WO2001004308A1 Human lim domain proteins |
| 01/18/2001 | WO2001004305A2 Human proteins involved in detoxification |
| 01/18/2001 | WO2001004297A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 01/18/2001 | WO2001004156A1 Peptides that lower blood glucose levels |
| 01/18/2001 | WO2001004124A1 OXATHIEPINO[6,5-b]DIHYDROPYRIDINES, AND RELATED COMPOSITIONS AND METHODS |
| 01/18/2001 | WO2001004122A2 New 2,3-benzodiazepine derivatives |
| 01/18/2001 | WO2001004118A2 Quinuclidine derivatives and their use as muscarinic m3 receptor ligands |
| 01/18/2001 | WO2001004099A1 Benzoylpyridazines |
| 01/18/2001 | WO2001003742A1 Drug composition for topical administration |
| 01/18/2001 | WO2001003740A1 Serine protease inhibitor |
| 01/18/2001 | WO2001003724A1 Therapeutic uses of bpi protein products for inhibiting h+/k+ atpase activity |
| 01/18/2001 | WO2001003720A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | WO2001003712A1 Composition containing extracts of butyrospermum parkii and the use as medicament or dietary supplement |
| 01/18/2001 | WO2001003707A1 Heartburn treatment |
| 01/18/2001 | WO2001003705A1 Compositions and methods for raising hdl cholesterol levels |
| 01/18/2001 | WO2001003703A1 An oral composition having as a first active ingredient rofleponide and as a second active ingredient an antibiotic, for use in intestinal conditions, especially crohn's disease |
| 01/18/2001 | WO2001003702A1 Pharmaceutical formulations comprising a glucocorticosteroid and an antifungal azole, for increasing the local mucosal tissue concentration of glucocorticosteroids in the gi tract |
| 01/18/2001 | WO2001003701A1 An oral composition having as a first active ingredient budesonide and as a second active ingredient an antibiotic, for use in intestinal conditions, especially crohn's disease |
| 01/18/2001 | WO2001003696A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 01/18/2001 | WO2001003688A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 01/18/2001 | WO2001003669A2 Delivery of liposomal-encapsulated antioxidants and applications thereof |
| 01/18/2001 | WO2001003668A1 Pulmonary delivery of liposome-encapsulated cannabinoids |
| 01/18/2001 | WO2000063415A8 Dna encoding the human vanilloid receptor vr1 |
| 01/18/2001 | WO2000055180A3 Human lung cancer associated gene sequences and polypeptides |
| 01/18/2001 | WO2000051631A3 Pegylated alpha interferon for hiv therapy |
| 01/18/2001 | CA2680437A1 Peptides that lower blood glucose levels |
| 01/18/2001 | CA2379199A1 Oxathiepino[6,5-b]dihydropyridines, and related compositions and methods |
| 01/18/2001 | CA2379133A1 Human proteins involved in detoxification |
| 01/18/2001 | CA2378989A1 Human lim domain proteins |
| 01/18/2001 | CA2378595A1 Benzoylpyridazines |
| 01/18/2001 | CA2378567A1 Novel myxoma genes for immune modulation |
| 01/18/2001 | CA2378305A1 New 2,3-benzodiazepine derivatives |
| 01/18/2001 | CA2378179A1 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | CA2378018A1 Heartburn treatment |
| 01/18/2001 | CA2377999A1 Compositions and methods for raising hdl cholesterol levels |
| 01/18/2001 | CA2377502A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 01/18/2001 | CA2341035A1 Pulmonary delivery of liposomal-encapsulated cannabinoids |
| 01/18/2001 | CA2340757A1 Delivery of liposomal-encapsulated antioxidants and applications thereof |
| 01/17/2001 | EP1069124A1 2-Benzimidazolylamine compounds as ORL1-receptor agonists |
| 01/17/2001 | EP1069114A2 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 01/17/2001 | EP1068869A2 Method and composition for ameliorating tissue damage due to ischemia and reperfusion |
| 01/17/2001 | EP1068867A2 Pharmaceutical tablet comprising an NSAID and misoprostol |
| 01/17/2001 | EP1068212A1 THIAZOLO 4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS |
| 01/17/2001 | EP1068207A1 AMINOALKYL SUBSTITUTED 9H-PYRIDINO 2,3-b]INDOLE AND 9H-PYRIMIDINO 4,5-b]INDOLE DERIVATIVES |
| 01/17/2001 | EP1068206A1 Aminoalkyl substituted pyrrolo 2,3-b]pyridine and pyrrolo 2,3-d]pyrimidine derivatives: modulators of crf1 receptors |
| 01/17/2001 | EP1068205A1 Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino 2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino 4,5-b]indole derivatives: crf1 specific ligands |
| 01/17/2001 | EP1068196A1 Nitrate salt of anti-ulcer medicine |
| 01/17/2001 | EP1068195A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1068180A1 Process for alkylating hindered sulfonamides useful in the production of matrix metalloprotenase inhibitors |
| 01/17/2001 | EP1067940A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 01/17/2001 | EP1067931A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067930A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067927A1 Antioxidant stabilizer system for pharmaceutical formulations |
| 01/17/2001 | EP1067906A1 Maximizing effectiveness of substances used to improve health and well being |
| 01/17/2001 | EP1067894A2 Protease inhibitors |
| 01/17/2001 | EP0983258A4 N-hydroxy 4-sulfonyl butanamide compounds |
| 01/17/2001 | EP0790998B1 Azo derivatives of 5-aminosalicylic acid for treatment of inflammatory bowel disease |
| 01/17/2001 | CN1280577A Benzodioxan, benzofuran or benzopyranl derivatives having fundic relaxation properties |
| 01/17/2001 | CN1280568A Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| 01/17/2001 | CN1280506A Oral Preparation |
| 01/17/2001 | CN1280011A Double expression process of producing hepatitis B virus vaccine |
| 01/17/2001 | CN1280006A Medicine ointment prepared with kapur and other Chinese herbal medicine |
| 01/17/2001 | CN1279991A Chinese medicine preparation for curing hepatitis B and other hepatic diseases |
| 01/17/2001 | CN1279982A Draco nis sanguis micro sponge agent and its preparing technology |
| 01/17/2001 | CN1279978A Ginkgo and gastrodia taber capsule |
| 01/17/2001 | CN1279975A Medicine for curing stomatocase |
| 01/17/2001 | CN1279973A Growth promoter for children |
| 01/17/2001 | CN1279962A Chinese medicine preparation for curing mucosa ulcer |
| 01/17/2001 | CN1279946A Berberine hydrochloride suppository and its producing method |
| 01/17/2001 | CN1279945A Gastric floating slow-releasing tinidazole capsule and its preparing method |
| 01/17/2001 | CN1279943A Concentrated granule medicine of famous decoction formulation and its preparation |
| 01/17/2001 | CN1060773C Naphthamide derivatives of 3-beta-amino azabicyclo octane or nonane as heuroleptic agents |
| 01/17/2001 | CN1060768C Pyrazoles and pyrazolopyrimidines |
| 01/17/2001 | CN1060764C Ortho-substituted benzoylguanidine, preparation method, use as medicine or diagnostic reagent and medicine containing them |
| 01/17/2001 | CN1060763C Urea-substituted benzoylguanidines, process for their preparation, and use and pharmaceutical containing them |
| 01/17/2001 | CN1060663C Compound Tibet capillary artemisia patent medicine |
| 01/17/2001 | CN1060656C Yuganwan pill-medicine for hepatitis |
| 01/17/2001 | CN1060655C Medicime for curing hepatitis |
| 01/16/2001 | US6175021 Human non-pancreatic secretory phospholipase a2 (spla2); inhibits release of arachidonic acid to treat septic shock; ((3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1h-indol-4 -yl)oxylacetic acid, for example |
| 01/16/2001 | US6175013 1-(2-methoxybenzyl)-2-((4-phenyl-1-piperazinyl)methyl)-4-(1h -indol-3-ylmethyl)-2-imidazoline, for example; adminstering to treat anxiety, depression, psychosis, and schizophrenia |
| 01/16/2001 | US6174993 Short peptides which selectively modulate the activity of serine/threonine kinases |
| 01/16/2001 | US6174896 Quinuclidine derivatives and medicinal composition thereof |
| 01/16/2001 | US6174895 1-aryl-3-arylmethyl-1,8-naphthyridin-4(1H)-ones |
| 01/16/2001 | US6174890 A synergistic biological, neurometabolic and celltrophic composition comprising antioxidative and -catabolic stress (methionine),-anabolic drugs, vasodilative and normo-lipidemic drugs (nicotinic acid), energoactive and antitoxic |
| 01/16/2001 | US6174887 Amide compounds and use of the same |
| 01/16/2001 | US6174868 Compositions and methods for treatment of hepatitis C virus-associated diseases |
| 01/16/2001 | US6174867 Inhibition of the binding of a toxin or organism to its corresponding cell surface receptor; e.g., heat-labile enterotoxin or cholera toxin or enterovirulent organisms; bactericides, viricides, fungicides |